Mast cell disorders constitute a heterogeneous group of diseases, including : * mastocytosis, i.e. cutaneous, indolent and severe forms of the disease, such as aggressive mastocytosis and mast cell leukemia) ; * mast cell-associated diseases such as mast cell activation syndrome (idiopathic, secondary or clonal), affecting both children and adults. No epidemiological data are currently available in France. In France, medical care of mast cell disorders is mainly provided by a rare disease network (CEREMAST), whose CRMR is located at the Necker Enfants Malades hospital in Paris. A total of 20 centers are located throughout France. Our aim is to use this network to study patients suffering from these diseases. The overall aim of the study is to improve the understanding, diagnosis, prognosis, recognition and management of patients with mastocytosis.
Study Type
OBSERVATIONAL
Enrollment
13,000
CHU AMIENS site sud
Amiens, France
RECRUITINGChu Angers
Angers, France
RECRUITINGChu - Besancon
Besançon, France
RECRUITINGChu - Caen
Caen, France
RECRUITINGChu - Clermont Ferrand
Clermont-Ferrand, France
RECRUITINGCHU Grenoble
Grenoble, France
RECRUITINGChru Lille
Lille, France
RECRUITINGChu - Limoges
Limoges, France
RECRUITINGHospices Civils de Lyon
Lyon, France
RECRUITINGChu - La Timone - Marseille
Marseille, France
RECRUITING...and 10 more locations
Epidemiology of mast cell disorders in France assessed by statistics on the prevalence on the various types of mast cell disorders
Time frame: Data 2010 - 2038
Epidemiology of mast cell disorders in France assessed by statistics on the incidence on the various types of mast cell disorders
Time frame: Data 2010 - 2038
Patient characteristics
age, gender, personal and family medical history
Time frame: Data 2010 - 2038
Characteristics of mast cell disease assessed by type of disease
Time frame: Data 2010 - 2038
Characteristics of mast cell disease assessed by diagnostic criteria
Time frame: Data 2010 - 2038
Characteristics of mast cell disease assessed by symptoms of disease
Time frame: Data 2010 - 2038
Evolution of mast cell disease assessed by progression of skin lesions
Time frame: Data 2010 - 2038
Evolution of mast cell disease assessed by progression to aggressive form
Time frame: Data 2010 - 2038
Evolution of mast cell disease assessed by associated hemopathy
Time frame: Data 2010 - 2038
Evolution of mast cell disease assessed by appearance of new symptoms
Time frame: Data 2010 - 2038
Patient follow-up assessed by occurrence of other medical events in the patient
Time frame: Data 2010 - 2038
Patient follow-up assessed by overall survival
Time frame: Data 2010 - 2038
Types of treatment used on mastocytosis and any associated hemopathy
Time frame: Data 2010 - 2038
Tolerance of treatment used on mastocytosis and any associated hemopathy
Time frame: Data 2010 - 2038
Efficacy of treatment used on mastocytosis and any associated hemopathy
Time frame: Data 2010 - 2038
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.